Polymorphism (C677T) in the 5,10-Methylenetetrahydrofolate reductase (MTHFR) gene: A preliminary study on north Indian men

被引：7

作者：

Vasisht S. ^{[1
]}

Gulati R. ^{[1
]}

Narang R. ^{[1
]}

Srivastava N. ^{[1
]}

Srivastava L.M. ^{[1
]}

Manchanda S.C. ^{[1
]}

Agarwal D.P. ^{[2
]}

机构：

[1] Department of Cardiology, Cardio-Thoracic and Neuro-Sciences Center, All India Institute of Medical Sciences, Ansari Nagar

[2] Institute of Human Genetics, Hamburg

来源：

Indian Journal of Clinical Biochemistry | 2002年 / 17卷 / 1期

关键词：

Atherosclerosis; Cardiovascular disease; Genetic polymorphism; Hyperhomocysteinemia;

D O I：

10.1007/BF02867949

中图分类号：

学科分类号：

摘要：

An elevated level of plasma homocysteine, sulfur containing amino acid generated through demethylation of methionine has been widely accepted as a risk factor for cardiovascular disease (CVD). The increase can result from genetic and/or nutrient related disturbances in the remethylation or transsulfuration pathways for homocysteine metabolism. A common mutation (C677T) in the gene encoding for the enzyme 5, 10-methylenetetrahydrofolate reductase (MTHFR) or deficiency of the B vitamins namely folic acid, B12, B6 can lead to hyperhomocysteinemia. In the present study, we have investigated the incidence of the (C677T) MTHFR polymorphism in the North Indian males. 141 angiographically proven coronary artery disease (CAD) patients and 55 age and sex matched healthy volunteers were examined for the association between MTHFR gene polymorphism and CAD. The MTHFR genotyping was performed using polymerase chain reaction (PCR) followed by restriction-isotyping with Hinf 1 endonuclease. A trend for higher T allele frequency (0.19) was observed in patients than in controls (0.16). However no significant association was found between C677T mutation and CAD severity. The lack of statistical significance could be due to the small sample size studied. Hence a larger study including various ethnic groups is warranted.

引用

页码：99 / 107

页数：8

共 22 条

[1]

Langman L.J., Cole D.E.C., Homocysteine: Cholesterol of the 90s, Clinica Chimica Acta, 286, pp. 63-80, (1990)

[2]

Pandey R., Gupta S., Lal H., Mehta H.C., Aggarwal S.K., Hyperhomocysteinemia and cardiovascular disease. The nutritional perspectives, Indian J. Clin. Biochem, 15, SUPPL., pp. 20-30, (2000)

[3]

DeVigneaud V.E., Trail of research in sulfur chemistry metabolism and related fields, (1952)

[4]

Gerristen T., Waisman H.A., Homocystinuria an error in the metabolism of methionine, Pediatrics, 33, pp. 413-420, (1964)

[5]

Ma J., Stampfer M.J., Hennekens C.H., Frost P., Selhub J., Horsford J., Malinow M.R., Willett W.C., Rozen R., Methylenetetrahydrofolate reductase polymorphism, plasma foliate, homocysteine and risk of myocardial infarction in US physicians, Circulation, 94, pp. 2410-2416, (1996)

[6]

Carson N.A.J., Neil D.W., Metabolic abnormalities detected in a survey of mentally backward individuals in Northern Ireland, Arch. Dis. Child, 37, pp. 505-513, (1962)

[7]

McCully K.S., Vascular pathology of homocysteinemia, implication for the pathogenesis of arteriosclerosis, Am. J. Pathol, 56, pp. 111-128, (1969)

[8]

Jacobsen D.W., Homocysteine and vitamins in cardiovascular disease, Clin. Chem, 44, pp. 1833-1843, (1998)

[9]

Ueland P.M., Refsum H., Plasma homocysteine a risk factor for vascular disease: Plasma levels in health, disease and drug therapy, J. Lab. Clin. Med, 114, pp. 473-501, (1989)

[10]

Goyettte P., Pai A., Milos R., Frost P., Tran P., Chen Z., Chan M., Rozen R., Gene structure of human and mouse methylenetetrahydrofolate reductase (MTHFR), Mammalian Genome, 9, pp. 652-656, (1998)

← 1 2 3 →